Chemotherapy Liberates a Broadening Repertoire of Tumor Antigens for TLR7/8/9-Mediated Potent Antitumor Immunity
Chemotherapie setzt ein sich verbreiterndes Repertoire an Tumorantigenen für eine TLR7/8/9-vermittelte starke Antitumorimmunität frei
Cancers · 09.10.2025 · 17 (19) · 3277
DOI: 10.3390/cancers17193277 ↗Auf einen Blick
In Mausmodellen verstärkte Chemotherapie mit dem TLR7/8/9-Agonisten CR108 die Antigenverfügbarkeit und T-Zell-Antworten. Platinpräparate zeigten dabei die größte Zunahme löslicher Tumorantigene.
Fragestellung
Fördert Chemotherapie zusammen mit dem TLR7/8/9-Agonisten CR108 die Antitumorimmunität über eine breitere Freisetzung von Tumorantigenen?
Methode
Mausmodelle für Brustkrebs (4T1), Melanom (B16-F10) und Kolorektalkarzinom (CT26); verschiedene Chemotherapeutika plus CR108; Analyse von Tumorantigenen, T-Zell-Antworten, Zytokinen und TCRβ-Repertoire.
Ergebnisse
Chemotherapie plus CR108 erhöhte die T-Zell-Erkennung von Kandidaten-TAs und IFN-γ+ CD8+ Antworten. TCRβ-Sequenzierung zeigte mehr klonale Amplitude ohne Verlust der Repertoirebreite; Platinpräparate erhöhten lösliche TAs am stärksten.
Schlussfolgerung der Autor:innen
Die Autor:innen sehen einen antigenspezifischen Mechanismus der chemo-TLR-Agonisten-Synergie: Chemotherapie setzt breitere Tumorantigene frei, die CR108 über angeborene Immunaktivierung für eine starke T-Zell-Antitumorantwort nutzt.
Kernaussagen
- Chemotherapie + CR108 verstärkte Antigenverfügbarkeit und T-Zell-Antworten
- Platinpräparate erzeugten die größte Zunahme löslicher Tumorantigene
- Therapieerfolg korrelierte mit Antigenverfügbarkeit und -verarbeitung
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 09.10.2025. Verfasst von Cheng Zu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai 200032, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Science and Technology Commission of Shanghai Municipality, Fudan-Advaccine Join-Laboratory Innovation Grant.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Most immunologically “cold” tumors do not respond durably to checkpoint blockade because tumor antigen (TA) release and presentation are insufficient to prime effective T-cell immunity. While prior work demonstrated synergy between cisplatin and a TLR7/8/9 agonist (CR108) in 4T1 tumors, the underlying mechanism—particularly whether chemotherapy functions as a broad antigen-releasing agent enabling TLR-driven immune amplification—remained undefined.
Methods
Using murine models of breast (4T1), melanoma (B16-F10), and colorectal cancer (CT26), we tested multiple chemotherapeutic classes combined with CR108. We quantified intratumoral and systemic soluble TAs, antigen presentation and cross-priming by antigen-presenting cells, tumor-infiltrating lymphocytes, and cytokine production by flow cytometry/ICS. T-cell receptor β (TCRβ) repertoire dynamics in tumor-draining lymph nodes were profiled to assess amplitude and breadth. Tumor microenvironment remodeling was analyzed, and public datasets (e.g., TCGA basal-like breast cancer) were interrogated for expression of genes linked to TA generation/processing and peptide loading.
Results
Using cisplatin + CR108 in 4T1 as a benchmark, we demonstrate that diverse chemotherapies—especially platinum agents—broadly increase the repertoire of soluble tumor antigens available for immune recognition. Across regimens, chemotherapy combined with CR108 increased T-cell recognition of candidate TAs and enhanced IFN-γ+ CD8+ responses, with platinum agents producing the largest expansions in soluble TAs. TCRβ sequencing revealed increased clonal amplitude without loss of repertoire breadth, indicating focused yet diverse antitumor T-cell expansion. Notably, therapeutic efficacy was not predicted by canonical damage-associated molecular pattern (DAMP) signatures but instead correlated with antigen availability and processing capacity. In human basal-like breast cancer, higher expression of genes involved in TA generation and antigen processing/presentation correlated with improved survival.
Conclusions
Our findings establish an antigen-centric mechanism underlying chemo–TLR agonist synergy: chemotherapy liberates a broadened repertoire of tumor antigens, which CR108 then leverages via innate immune activation to drive potent, T-cell-mediated antitumor immunity. This framework for rational selection of chemotherapy partners for TLR7/8/9 agonism and support clinical evaluation to convert “cold” tumors into immunologically responsive disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai 200032, China.
- Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
- Advaccine Biopharmaceuticals Suzhou Co., Ltd., Suzhou 215000, China.
Förderung
- National Science and Technology Council
- Science and Technology Commission of Shanghai Municipality
- Fudan-Advaccine Join-Laboratory Innovation Grant
- Ministry of Science and Technology of the People’s Republic of China
- Shanghai Municipal Science and Technology Major Project
Zitieren
APA
Zu, C., Zhong, Y., Wu, S., & Wang, B. (2025). Chemotherapy Liberates a Broadening Repertoire of Tumor Antigens for TLR7/8/9-Mediated Potent Antitumor Immunity. Cancers, 17(19), 3277. https://doi.org/10.3390/cancers17193277
Vancouver
Zu C, Zhong Y, Wu S, Wang B. Chemotherapy Liberates a Broadening Repertoire of Tumor Antigens for TLR7/8/9-Mediated Potent Antitumor Immunity. Cancers. 2025;17(19):3277. doi:10.3390/cancers17193277
BibTeX
@article{Zu2025,
author = {Zu, Cheng and Zhong, Yiwei and Wu, Shuting and Wang, Bin},
title = {Chemotherapy Liberates a Broadening Repertoire of Tumor Antigens for TLR7/8/9-Mediated Potent Antitumor Immunity},
journal = {Cancers},
year = {2025},
volume = {17},
number = {19},
pages = {3277},
doi = {10.3390/cancers17193277}
}
EUVIMED